Genprex (GNPX) vs Oragenics (OGEN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Genprex is the larger company by market cap ($2.3 million vs $2.1 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | GNPX | OGEN |
|---|---|---|
| Share price | $2.75 | $0.463 |
| Market cap | $2.25M | $2.09M |
| 1-day change | +4.96% | -7.38% |
| EPS (TTM) | $-9.35 | $-2.44 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $1,210.00 | $1.45 |
| 52-week low | $2.53 | $0.46 |
| Distance from 52-week high | -99.77% | -68.07% |
| Average volume | 247.06K | 29.43K |
| Shares outstanding | 819.71K | 4.51M |
| Employees | 13 | 3 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Genprex
GNPX stock →Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. The company's technologies are designed to administer disease-fighting genes to provide new therapies for patient populations with cancer and diabetes.
Health Care · Biotechnology: Pharmaceutical Preparations · 13 employees
About Oragenics
OGEN stock →Oragenics, Inc., a development-stage company, engages in the research and development of nasal delivery pharmaceutical therapies neurological conditions and infectious diseases in the United States. Its lead product is ONP-002, a fully synthetic, non-naturally occurring neurosteroid, which is lipophilic and can cross the blood-brain barrier to reduce swelling, oxidative stress, and inflammation while restoring proper blood flow through gene amplification for the treatment of mild traumatic brain injury.
Health Care · Biotechnology: Pharmaceutical Preparations · 3 employees
GNPX vs OGEN FAQ
Which is bigger, Genprex or Oragenics?
Genprex (GNPX) is larger, with a market capitalization of $2.25M compared with $2.09M for Oragenics (OGEN).
Are Genprex and Oragenics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.